disitamab vedotin + toripalimab + trastuzumab

disitamab vedotin + toripalimab + trastuzumab is a combination regimen consisting of three drugs: - **disitamab vedotin**: an antibody-drug conjugate (ADC) targeting HER2. It uses a humanized anti-HER2 antibody (disitamab; hertuzumab) conjugated via a valine-citrulline linker to the cytotoxic payload monomethyl auristatin E (MMAE), which inhibits microtubule polymerization, leading to cancer cell death[5]. - **toripalimab**: a monoclonal antibody acting as an immune checkpoint inhibitor that binds to PD-1 on T cells, thereby blocking the interaction between PD-1 and its ligands, enhancing immune response against cancer cells[1]. - **trastuzumab**: a monoclonal antibody targeting HER2, leading to inhibition of signaling pathways, antibody-dependent cellular cytotoxicity, and cell cycle arrest in HER2-overexpressing tumors[5]. This triplet regimen is primarily under evaluation as a first-line therapy for patients with locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinomas expressing HER2, either highly or at median/low levels. The combination offers superior objective response rates and progression-free survival compared to regimens omitting one of the targeted agents or replacing one with chemotherapy[1][2][4].